ストックスクリーナーアプリを入手
5.00
1.21%
0.06
アフターアワーズ：
4.98
-0.02
-0.40%
前日終値:
$4.94
開ける：
$4.9
24時間の取引高:
187.78K
Relative Volume:
0.76
時価総額：
$55.44M
収益：
$52.29M
当期純損益:
$-73.52M
株価収益率:
-7.5758
EPS:
-0.66
ネットキャッシュフロー:
$-100.45M
1週間 パフォーマンス:
+7.76%
1か月 パフォーマンス:
+9.41%
6か月 パフォーマンス:
-1.57%
1年 パフォーマンス:
-49.75%
1日の値動き範囲:
$4.85
$5.10
1週間の範囲:
$4.4601
$5.2499
52週間の値動き範囲:
$3.61
$11.09
Precision Biosciences Inc Stock (DTIL) Company Profile
名前
Precision Biosciences Inc
セクター
電話
919-314-5512
住所
302 EAST PETTIGREW STREET, DURHAM, NC
DTIL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.00 | 53.89M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 開始されました | Guggenheim | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-06-09 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 再開されました | BTIG Research | Buy |
| 2020-04-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-05 | 開始されました | Stifel | Buy |
| 2020-02-25 | 開始されました | William Blair | Outperform |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-22 | 開始されました | Barclays | Overweight |
| 2019-04-22 | 開始されました | Goldman | Buy |
| 2019-04-22 | 開始されました | JP Morgan | Overweight |
| 2019-04-22 | 開始されました | Jefferies | Buy |
すべてを表示
Precision Biosciences Inc (DTIL) 最新ニュース
Precision BioSciences shares climb after FDA grants orphan drug status - MSN
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD - Contract Pharma
Precision Biosciences’ PBGENE-DMD gains US orphan drug designation - BioWorld MedTech
What analysts say about Precision BioSciences Inc. stockFree Trading Strategy Suggestions - Autocar Professional
Precision BioSciences stock rises after FDA grants orphan drug status By Investing.com - Investing.com Canada
FDA grants orphan drug status to Precision BioSciences’ DMD treatment - Investing.com Australia
FDA grants orphan drug status to Precision BioSciences’ DMD treatment By Investing.com - Investing.com Nigeria
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
What drives Precision BioSciences Inc. stock priceFastest return on investment - jammulinksnews.com
Precision BioSciences Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com
Precision BioSciences Secures Orphan Drug Designation for DMD Treatment, DTIL Stock News - AInvest
Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status - TipRanks
Precision BioSciences gets FDA orphan drug designations for DMD treatment By Investing.com - Investing.com Canada
Precision BioSciences reports promising DMD gene editing results By Investing.com - Investing.com Canada
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire
How Precision BioSciences Inc. stock performs during market volatilityFree Market Sentiment Analysis - Newser
Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’ - MSN
Why Precision BioSciences Inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
What makes Precision BioSciences Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
(DTIL) Proactive Strategies - news.stocktradersdaily.com
Precision Biosciences CFO Sells Shares to Cover Tax Obligations - TradingView
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 3000E Value Index - MarketScreener
Insider Buying: Kevin Buehler Acquires Shares of Precision BioSciences Inc (DTIL) - GuruFocus
Precision Biosciences director Brown buys $6963 in DTIL stock - Investing.com
Precision BioSciences stock jumps after FDA grants rare pediatric designation By Investing.com - Investing.com UK
A startup banks $66M to pursue ‘inclusive precision medicine’ - BioPharma Dive
precision biosciences reports voting outcomes at annual shareholder meeting By Investing.com - Investing.com Australia
precision biosciences reports voting outcomes at annual shareholder meeting - Investing.com
Precision BioSciences Holds Annual Stockholder Meeting - TipRanks
Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus
Precision BioSciences: Q1 Earnings Snapshot - CT Insider
Precision BioSciences Reports Q1 2025 Financial Results - TipRanks
Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Precision BioSciences Reports Q1 Results and Business Update - TipRanks
Precision Biosciences Inc (DTIL) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):